FrancophonIA/ELRC3.0 huggingface dataset:
English: Ototoxicity has been associated with glycopeptide use (vancomycin and teicoplanin); patients who are receiving concomitant therapy with an ototoxic medicinal product, such as an aminoglycoside, may be at increased risk.
Danish: Ototoksicitet er blevet knyttet til behandling med glykopeptider (vancomycin og teicoplanin); patienter, som samtidig får et ototoksisk lægemiddel, som fx et aminoglykosid, kan have en større risiko.
English: All Gram-negative bacteria are inherently resistant to dalbavancin.
Danish: Alle gramnegative bakterier er naturligt resistente over for dalbavancin.
English: Clinical efficacy against specific pathogens
Danish: Klinisk virkning mod bestemte patogener
English: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Danish: Ikke anvendte lægemidler eller affald heraf bør bortskaffes i henhold til lokale retningslinjer.
English: Dalbavancin should be administered with caution in patients known to be hypersensitive to other glycopeptides since cross-hypersensitivity may occur.
Danish: Dalbavancin skal gives med forsigtighed til patienter med overfølsomhed over for andre glykopeptider, da der kan optræde krydsallergi.
English: It may affect up to 1 in 1,000 people.
Danish: Den kan ramme op til 1 ud af 1.000 behandlede.
English: Xydalba may have a minor influence on the ability to drive and use machines, as dizziness has been reported in a small number of patients (see section 4.8).
Danish: Xydalba kan i mindre grad påvirke evnen til at føre motorkøretøj og betjene maskiner, da svimmelhed er blevet rapporteret hos et mindre antal patienter (se pkt.
English: and Enterococcus spp.
Danish: og Enterococcus spp.
English: Tell your doctor or nurse immediately if you are concerned that you are missing the 2nd dose.
Danish: Fortæl øjeblikkeligt din læge eller sundhedspersonalet, hvis du er bekymret over, at du mangler at få den anden dosis.
English: In Phase 1 studies, healthy volunteers have been administered single doses of up to 1,500 mg, and cumulative doses up to 4,500 mg over a period of up to 8 weeks, with no signs of toxicity or laboratory results of clinical concern.
Danish: I fase 1-studier er raske forsøgspersoner blevet givet enkeltdoser på op til 1.500 mg og kumulative doser på op til 4.500 mg i en periode på op til 8 uger uden tegn på toksicitet eller laboratorieafvigelser af klinisk betydning.
English: Clinical efficacy has not been established against the following pathogens although in vitro studies suggest that they would be susceptible to dalbavancin in the absence of acquired mechanisms of resistance:
Danish: Der er ikke påvist klinisk virkning mod følgende patogener, selvom in vitro studier indikerer, at de ville være følsomme for dalbavancin i fravær af erhvervede resistensmekanismer:
English: However, dalbavancin is excreted in the milk of lactating rats and may be excreted in human breast milk.
Danish: Dalbavancin udskilles imidlertid i mælken hos ammende rotter, og det er derfor muligt, at det også udskilles i human mælk.
English: In rats, at exposures approximately 3 times above clinical exposure, there was reduced fertility and an increased incidence of embryo-lethality, reductions in foetal weight and skeletal ossification and increased neonatal mortality.
Danish: Ved en eksponering på omkring 3 gange over den kliniske eksponering sås hos rotter reduceret fertilitet og øget forekomst af embryoletalitet, reduceret fostervægt og skeletal ossifikation samt øget neonatal mortalitet.
English: Xydalba is used to treat adults with infections of the skin or in the layers of flesh below the skin.
Danish: Xydalba bruges til voksne med hudinfektioner eller infektioner i lagene under huden.
English: The mean AUC for subjects with creatinine clearance < 30 ml/min was approximately 2 - fold higher.
Danish: Middel-AUC for personer med kreatininclearance < 30 ml/min var omkring 2 gange højere.
English: You should not breastfeed when given Xydalba.
Danish: Du bør ikke amme, mens du får Xydalba.
English: Diarrhoea during or after treatment If you develop diarrhoea during or after your treatment, tell your doctor at once.
Danish: Hvis du får diarré under eller efter behandlingen, skal du kontakte din læge øjeblikkeligt.
English: Information on the efficacy and safety of dalbavancin in patients with creatinine clearance < 30 ml/min is limited.
Danish: Der er begrænset information om dalbavancins virkning og sikkerhed hos patienter med kreatininclearance < 30 ml/min.
English: The mean AUC was unchanged in subjects with mild hepatic impairment compared to subjects with normal hepatic function; however, the mean AUC decreased by 28 % and 31 %, respectively, in subjects with moderate and severe hepatic impairment.
Danish: Middel-AUC var uændret hos personer med let nedsat leverfunktion sammenlignet med personer med normal leverfunktion; middel-AUC faldt dog med hhv. 28 % og 31 % hos personer med moderat til svært nedsat leverfunktion.
English: The volume of distribution at steady state was similar to the volume of extracellular fluid.
Danish: Fordelingsvolumen ved steady state svarede til det ekstracellulær væskevolumen.
English: The pharmacokinetics of dalbavancin were evaluated in 28 subjects with varying degrees of renal impairment and in 15 matched control subjects with normal renal function.
Danish: Dalbavancins farmakokinetiske egenskaber blev evalueret hos 28 personer med forskellige grader af nyreinsufficiens og hos 15 matchede kontrolpersoner med normal nyrefunktion.
English: Hydroxy-dalbavancin and mannosyl aglycone show significantly less antibacterial activity compared to dalbavancin.
Danish: Hydroxydalbavancin og mannosylaglykon viser signifikant lavere antibakteriel aktivitet end dalbavancin.
English: • The other ingredients are mannitol (E421), lactose monohydrate, hydrochloric acid and/or sodium hydroxide (for pH adjustment only).
Danish: • Øvrige indholdsstoffer: mannitol (E421), lactosemonohydrat, saltsyre og/eller natriumhydroxid (til pH-justering)
English: Xydalba may cause dizziness.
Danish: Xydalba kan forårsage svimmelhed.
English: Infection of the bowel has been reported as an uncommon side effect.
Danish: Tarminfektion er blevet rapporteret som en ikke almindelig bivirkning.
English: (mg•h/L)
Danish: (mg•time/l)
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial label
Danish: MINDSTEKRAV TIL MÆRKNING PÅ SMÅ INDRE EMBALLAGER HÆTTEGLASETIKET
English: Depending on the condition of your kidney, your doctor may have to reduce your dose.
Danish: Afhængigt af dine nyrers tilstand, kan lægen beslutte at reducere din dosis.
English: It is unknown whether dalbavancin is excreted in human milk.
Danish: Det er ukendt, om dalbavancin udskilles i human mælk.
English: Dalbavancin Plasma Concentrations versus time in a typical ABSSSI patient (simulation using population pharmacokinetic model) for both the single and the two-dose regimens.
Danish: Dalbavancin-plasmakoncentration i forhold til tid hos en typisk ABSSSI-patient (simulation, der anvender en populationsfarmakokinetisk model) for regime med henholdsvis en enkelt dosis og med to doser.
English: Intravenous infusions with these types of antibiotics can cause flushing of the upper body, hives, itching and/or rashes.
Danish: Intravenøse infusioner med denne type antibiotika kan forårsage rødme på overkroppen, nældefeber, udslæt og/eller kløe.
English: The pharmacokinetics of dalbavancin were evaluated in 17 subjects with mild, moderate, or severe hepatic impairment and compared to 9 matched healthy subjects with normal hepatic function.
Danish: Dalbavancins farmakokinetiske egenskaber blev evalueret hos 17 personer med let, moderat eller svært nedsat leverfunktion og sammenlignet med 9 matchede raske personer med normal leverfunktion.
English: Dalbavancin pharmacokinetics in subjects with end-stage renal disease receiving regularly scheduled renal dialysis (3 times/week) were similar to those observed in subjects with mild to moderate renal impairment, and less than 6 % of an administered dose is removed after 3 hours of haemodialysis.
Danish: Dalbavancins farmakokinetiske egenskaber hos personer med nyresygdom i slutstadiet, som er i regelmæssig dialyse (3 gange om ugen), svarede til dem, som blev observeret hos personer med let til moderat nedsat nyrefunktion, og mindre end 6 % af den administrerede dosis er fjernet efter 3 timers hæmodialyse.
English: Blood and lymphatic system disorders anaemia, thrombocytosis, eosinophilia, leucopenia, neutropenia
Danish: Blod- og lymfesystem anæmi, trombocytopeni, eosinofili, leukopeni, neutropeni
English: The clinical significance of the decrease in mean plasma CLT, and the associated increase in AUC0-∞ noted in these pharmacokinetic studies of dalbavancin in subjects with severe renal impairment has not been established.
Danish: Den kliniske relevans af faldet i middel-plasma-CLT og den associerede stigning i AUC0-∞, som blev fundet i disse farmokokinetiske studier med dalbavancin hos personer med svært nedsat nyrefunktion, er ikke blevet klarlagt.
English: • Sudden swelling of your lips, face, throat or tongue; severe rash; itchiness; throat tightening; drop in blood pressure; difficulty in swallowing and /or difficulty in breathing.
Danish: • Pludselig hævelse af læber, ansigt, hals eller tunge, alvorligt udslæt, kløe, snørende fornemmelse omkring halsen, blodtryksfald, synkeforstyrrelser og/eller vejrtrækningsbesvær.
English: You will be given Xydalba through a drip directly into your bloodstream through a vein (intravenously) over 30 minutes.
Danish: Du vil få Xydalba gennem et drop i en vene direkte ind i din blodbane (intravenøst).
English: Dose adjustments are not required for patients receiving regularly scheduled haemodialysis (3 times/week), and dalbavancin may be administered without regard to the timing of haemodialysis.
Danish: Dosisreduktion er ikke nødvendig hos patienter i regelmæssig hæmodialyse (3 gange om ugen), og dalbavancin kan administreres uden hensyn til hæmodialysetidspunkt.
English: 2 1,000 mg on Day 1 + 500 mg on Day 8; Study DUR001-303 subjects with evaluable PK sample.
Danish: 2 1.000 mg på Dag 1 + 500 mg på Dag 8; Studie DUR001-303 forsøgspersoner med en farmakokinetisk evaluerbar prøve.
English: Clinical drug-drug interaction studies with dalbavancin have not been conducted.
Danish: Der er ikke udført kliniske interaktionsstudier med dalbavancin.
English: Tell your doctor or pharmacist if you are taking, or have recently taken or might take any other medicines.
Danish: Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.
English: 3 1,500 mg; Study DUR001-303 subjects with evaluable PK sample.
Danish: 3 1.500 mg; Studie DUR001-303 forsøgspersoner med en farmakokinetisk evaluerbar prøve.
English: Xydalba is for single use only.
Danish: Xydalba er kun til engangsbrug.
English: It is not known if Xydalba passes into breast milk in humans.
Danish: Det er ukendt, om Xydalba udskilles i mælken i mennesker.
English: Clinically significant gender-related differences in dalbavancin pharmacokinetics have not been observed in healthy subjects or in patients with infections.
Danish: Der blev ikke observeret klinisk signifikante kønsrelaterede forskelle i dalbavancins farmakokinetiske egenskaber hos raske personer eller hos patienter med infektioner.
English: Efficacy has been demonstrated in clinical studies against the pathogens listed for ABSSSI that were susceptible to dalbavancin in vitro:
Danish: Kliniske studier har vist effektivitet mod patogener, anført for ABSSSI, som var følsomme for dalbavancin in vitro:
English: Mean plasma exposures for dalbavancin, based on AUCinf (17,495 µg•h/ml and 16,248 µg •h/ml) and Cmax (212 µg/ml and 191 µg/ml) were similar when administered as 1,000 mg to paediatric subjects (12-16 years) weighing > 60 kg (61.9 - 105.2 kg) or as 15 mg/kg to paediatric subjects weighing < 60 kg (47.9-58.9 kg).
Danish: Middel-plasmaeksponeringerne for dalbavancin, baseret på AUCinf (17.495 µg•time/ml og 16.248 µg •time/ml) og Cmax (212 µg/ml og 191 µg/ml) var sammenlignelige, når det blev administreret som 1.000 mg til pædiatriske patienter (12-16 år) med en vægt > 60 kg (61,9-105,2 kg) og som 15 mg/kg til pædiatriske patienter med en vægt < 60 kg (47,9-58,9 kg).
English: Following a single dose of 500 mg or 1,000 mg dalbavancin, the mean plasma clearance (CLT) was reduced 11 %, 35 %, and 47 % in subjects with mild (CLCR 50 - 79 ml/min), moderate (CLCR 30 - 49 ml/min), and severe (CLCR < 30 ml/min) renal impairment, respectively, compared to subjects with normal renal function.
Danish: Efter en enkelt dosis på 500 mg eller 1.000 mg dalbavancin blev middel-plasma-clearance (CLT) reduceret med hhv. 11 %, 35 % og 47 % hos personer med let (CLCR 50-79 ml/min), moderat (CLCR 30-49 ml/min) og svært (CLCR < 30 ml/min) nedsat nyrefunktion i forhold til personer med normal nyrefunktion.
English: Name and address of the manufacturer responsible for batch release
Danish: Navn og adresse på den fabrikant, der har ansvaret for batchfrigivelse
English: The safety and efficacy of dalbavancin in children aged from birth to < 18 years has not yet been established.
Danish: Dalbavancins sikkerhed og virkning hos børn fra fødsel til < 18 år er endnu ikke klarlagt.
English: Xydalba powder for concentrate for solution for infusion is provided in a 48 ml glass vial with a green flip off seal.
Danish: Xydalba pulver til koncentrat til infusionsvæske leveres i et hætteglas på 48 ml med grøn flip-offforsegling.
English: In dogs only, infusion reactions characterised by skin swelling and/or redness (not associated with the injection site), mucosal pallor, salivation, vomiting, sedation, and modest declines in blood pressure and increases in heart rate were observed in a dose-dependent manner.
Danish: Kun hos hunde blev der på en dosis-afhængig måde observeret infusionsreaktioner karakteriseret ved hævelse af hud og/eller rødme (ikke knyttet til injektionsstedet), blege slimhinder, savlen, opkastning, sedation samt moderat blodtryksfald og stigning i hjertefrekvens.
English: It may affect up to 1 in 100 people.
Danish: Den kan ramme op til 1 ud af 100 behandlede.
English: Intravenous use after reconstitution and dilution.
Danish: Intravenøs brug efter rekonstitution og fortynding.
English: The interaction potential of dalbavancin on medicinal products metabolised by CYP enzymes is expected to be low since it is neither an inhibitor nor an inducer of CYP enzymes in vitro.
Danish: Potentialet for interaktion mellem dalbavancin og lægemidler, der metaboliseres af CYP-enzymer, forventes at være lavt, da dalbavancin hverken hæmmer eller inducerer CYP-enzymer in vitro.
English: The vial contains white to off-white to pale yellow powder.
Danish: Hætteglasset indeholder hvidt til off-white til lysegult pulver.
English: Apparent terminal t½ was similar for dalbavancin doses of 1,000 mg and 15 mg/kg, with mean values of 227 and 202 hours, respectively.
Danish: De tilsyneladende terminale halveringstider var sammenlignelige ved doser på 1.000 mg og 15 mg/kg med middelværdier på hhv. 227 and 202 timer.
English: Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4.4 and 5.1).
Danish: Xydalba er indiceret til behandling af akutte bakterielle infektioner i hud og hudstrukturer (ABSSSI) hos voksne (se pkt.
English: Chemical and physical in-use stability of Xydalba has been demonstrated for both the reconstituted concentrate and for the diluted solution for 48 hours at or below 25 °C.
Danish: Der er vist kemisk og fysisk i-brug-stabilitet for Xydalba i 48 timer ved 25 °C eller derunder for både det rekonstituerede koncentrat og den fortyndede infusionsvæske.
English: No accumulation of dalbavancin was observed following multiple intravenous infusions administered once-weekly for up to 8 weeks (1,000 mg on Day 1, followed by up to 7 weekly 500 mg doses) in healthy adults.
Danish: Der blev ikke observeret akkumulation af dalbavancin efter flere intravenøse infusioner givet en gang om ugen i op til 8 uger (1.000 mg på dag 1 efterfulgt af op til 7 doser på 500 mg ugentligt) hos raske voksne.
English: Dalbavancin is not well absorbed orally; however, an impact on the gastrointestinal flora or mouth flora of a breast-feeding infant cannot be excluded.
Danish: Dalbavancin absorberes dårligt oralt, men en påvirkning af floraen i gastrointestinalkanalen og munden hos det ammede barn kan ikke udelukkes.
English: If a common intravenous line is being used to administer other medicinal products in addition to Xydalba, the line should be flushed before and after each Xydalba infusion with 5% glucose solution for infusion.
Danish: Hvis samme venekateter anvendes til administration af andre lægemidler foruden Xydalba, skal kateteret gennemskylles med 5 % glucose infusionsvæske, opløsning før og efter hver infusion af Xydalba.
English: For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Danish: Hvis du ønsker yderligere oplysninger om Xydalba, skal du henvende dig til den lokale repræsentant for indehaveren af markedsføringstilladelsen:
English: The experience with dalbavancin in elderly is limited: 276 patients ≥ 75 years of age were included in the Phase 2/3 clinical studies, of which 173 received dalbavancin.
Danish: 276 patienter ≥ 75 år deltog i kliniske fase 2/3-studier, og 173 fik dalbavancin.
English: A total of 10 paediatric patients with ages 12 to 16 years who had resolving infections were given single doses of either dalbavancin 1,000 mg (body weight ≥ 60 kg) or dalbavancin 15 mg/kg (body weight < 60 kg).
Danish: I alt 10 pædiatriske patienter i alderen fra 12 til 16 år, som havde infektion i bedring, blev givet en enkelt dosis på enten 1.000 mg dalbavancin (kropsvægt ≥ 60 kg) eller 15 mg/kg dalbavancin (kropsvægt < 60 kg).
English: • Viridans group streptococci (Streptococcus anginosus group only): Susceptible ≤ 0.125 mg/l; Resistant > 0.125 mg/l.
Danish: • Viridans-gruppe streptokokker (kun Streptococcus anginosus-gruppe): Følsom ≤ 0,125 mg/l; resistent > 0,125 mg/l.
English: Dalbavancin is not metabolised by CYP enzymes in vitro, therefore co-administered CYP inducers or inhibitors are unlikely to influence the pharmacokinetics of dalbavancin.
Danish: Dalbavancin metaboliseres ikke af CYP-enzymer in vitro, hvorfor samtidig administration af CYPinduktorer eller CYP-hæmmere sandsynligvis ikke har nogen indvirkning på dalbavancins farmakokinetik.
English: Rapid intravenous infusions of glycopeptide antibacterial agents can cause reactions that resemble “Red-Man Syndrome”, including flushing of the upper body, urticaria, pruritus, and/or rash.
Danish: Hurtig intravenøs infusion af glykopeptid-antibiotika kan medføre reaktioner, som minder om ”red man”-syndromet, dvs. kraftig rødme af overkroppen, urticaria, kløe og/eller hududslæt.
English: Single-use 48 ml type I glass vial with an elastomeric stopper and a green flip off seal.
Danish: 48 ml engangshætteglas (type i-glas) med elastomerprop og grøn flip-off-forsegling.
English: In Phase 2 / 3 clinical studies, 2,473 patients received dalbavancin administered as either a single infusion of 1,500 mg or as 1,000 mg followed one week later by 500 mg.
Danish: I kliniske fase 2/3-studier fik 2.473 patienter dalbavancin administreret enten som en enkelt infusion på 1.500 mg eller som 1.000 mg efterfulgt af 500 mg en uge senere.
English: The safety and efficacy of Xydalba in children aged from birth to < 18 years have not yet been established.
Danish: Xydalbas sikkerhed og virkning hos børn i alderen fra fødsel til < 18 år er endnu ikke klarlagt.
English: This medicinal product must not be mixed with other medicinal products or intravenous solutions other than those mentioned in section 6.6.
Danish: Dette lægemiddel må ikke blandes med andre lægemidler eller infusionsvæsker end dem, der er anført i pkt.
English: CL (L/h)
Danish: CL (l/time)
English: Elderly No dose adjustment is necessary (see section 5.2).
Danish: Ældre Dosisreduktion er ikke nødvendig (se pkt.
English: Interactions with other antibacterial agents
Danish: Interaktion med andre antibakterielle midler
English: Following a single intravenous dose of 1,000 mg in healthy volunteers AUC in skin blister fluid amounted (bound and unbound dalbavancin) to approximately 60 % of the plasma AUC at day 7 post-dose.
Danish: Efter en enkelt intravenøs dosis på 1.000 mg til raske personer blev AUC (bundet og ubundet dalbavancin) i blistervæske fundet til omkring 60 % af plasma-AUC på dag 7 efter dosering.
English: Dose-dependent toxicity included serum chemistry and histological evidence of renal and hepatic injury, reduced red blood cell parameters and injection site irritation.
Danish: Dosis-afhængig toksicitet omfatter blodkemi og histologisk evidens for nyre- og leverskade, reducerede erytrocyt-parametre og irritation ved injektionsstedet.
English: The prepared Xydalba solution for infusion must not be used if there are any particles or the solution is cloudy.
Danish: Den fortyndede Xydalba infusionsvæske må ikke anvendes, hvis der er synlige partikler, eller den er uklar.
English: Important: Please refer to the Summary of Product Characteristics (SmPC) before prescribing.
Danish: Vigtigt: Se produktresuméet før ordinering.
English: Potential for other medicinal products to affect the pharmacokinetics of dalbavancin.
Danish: Andre lægemidlers potentiale til at påvirke dalbavancins farmakokinetik
English: Sodium hydroxide and/or hydrochloric acid (for pH adjustment)
Danish: Natriumhydroxid og/eller saltsyre (til pH-justering)
English: Diarrhoea
Danish: • Diarré
English: No dose adjustment of dalbavancin is recommended for patients with mild hepatic impairment (Child-Pugh A).
Danish: Reduktion af dalbavancindosis er ikke nødvendig hos patienter med let nedsat leverfunktion (ChildPugh A).
English: Lactose monohydrate Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment)
Danish: Lactosemonohydrat Saltsyre (til pH-justering) Natriumhydroxid (til pH-justering)
English: • Beta-haemolytic streptococci of Groups A, B, C, G: Susceptible ≤ 0.125 mg/l; Resistant > 0.125 mg/l,
Danish: • Beta-hæmolytiske streptokokker gruppe A, B, C, G: Følsom ≤ 0,125 mg/l; resistent > 0,125 mg/l,
English: Estimated pharmacokinetic parameters of dalbavancin following the two-dose regimen and the single-dose regimen, respectively, are shown in Table 2 below.
Danish: Estimerede farmakokinetiske parametre for dalbavancin efter behandling med henholdsvis to doser og en enkelt dosis fremgår af tabel 2 nedenfor.
English: Dose adjustments are not required for patients with mild or moderate renal impairment (creatinine clearance ≥ 30 to 79 ml/min).
Danish: Dosisreduktion er ikke nødvendig hos patienter med let til moderat nedsat nyrefunktion (dvs. patienter med kreatininclearance ≥ på 30 til 79 ml/min).
English: If you miss a dose of Xydalba
Danish: Hvis du har glemt at få en dosis Xydalba
English: For example: 25 ml of the concentrate contains 500 mg dalbavancin.
Danish: For eksempel: 25 ml af koncentratet indeholder 500 mg dalbavancin.
English: In patients with chronic renal impairment whose creatinine clearance is < 30 ml/min and who are not receiving regularly scheduled haemodialysis, the recommended dose is reduced to either 1,000 mg administered as a single infusion or 750 mg followed one week later by 375 mg (see section 5.2).
Danish: Hos patienter med kronisk nedsat nyrefunktion med kreatininclearance < 30 ml/min, som ikke er i regelmæssig hæmodialyse, reduceres den anbefalede dosis til enten 1.000 mg administreret som en enkelt infusion eller til 750 mg efterfulgt af 375 mg en uge senere (se pkt.
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Danish: D. BETINGELSESR OG BEGRÆNSNINGER MED HENSYN TIL SIKKER OG EFFEKTIV ANVENDELSE AF LÆGEMIDLET
English: The dalbavancin plasma concentration-time following the two-dose and the single-dose regimens, respectively, are shown in Figure 1.
Danish: Plasmakoncentration-tid for dalbavancin efter behandling med henholdsvis to doser og en enkelt dosis fremgår af figur 1.